Hearn Jay Cho, MD, PhD

Hearn Jay Cho, MD, PhD, is chief medical officer at the Multiple Myeloma Research Foundation.

Articles by Hearn Jay Cho, MD, PhD

Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD

November 26th 2025

As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD.

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

ByRose McNulty,Hearn Jay Cho, MD, PhD

October 23rd 2025

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.

Hearn Jay Cho, MD, PhD

Articles by Hearn Jay Cho, MD, PhD

Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

Latest Updated Articles

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Defunding Co-Payment Assistance Disrupted nAMD Care

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer